10-K: VitaSpring Biomedical Files Delayed Annual Report

VitaSpring Biomedical Co., Ltd. has filed its delayed Form 10-K for the fiscal year ended January 31, 2025, detailing its development-stage status, ongoing financial challenges, and strategic focus on regenerative medicine.

Summary

• VitaSpring Biomedical Co., Ltd. filed its annual report on Form 10-K for the fiscal year ended January 31, 2025, after its original due date, stating it is working to regain full compliance with reporting obligations.
• The company remains in the development stage, with no revenue generated in fiscal years 2025 and 2024, and has incurred significant net losses.
• As of January 31, 2025, the company had minimal cash ($272), substantial liabilities ($4,029,578), and a stockholders' deficit ($4,015,200), leading to substantial doubt about its ability to continue as a going concern.
• The company's strategy focuses on research and development in cell-based technologies for regenerative medicine, preventive health, and functional wellness, particularly involving X.msc (mesenchymal stem cells) and exosomes.
• Significant related-party balances exist, including accounts payable and advances, with a recent deferred payment agreement for a substantial portion of the related-party debt.
• A material weakness in internal control over financial reporting was identified due to insufficient segregation of duties and lack of personnel with appropriate U.S. GAAP and SEC reporting expertise.
• The company has undergone a management change, with new leadership appointed in August 2025, and former officers and directors resigning.
• The company does not currently own any intellectual property and relies on trade secrets and proprietary know-how.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as highly negative due to the company's development-stage status, lack of revenue, significant financial distress, going concern issues, and identified material weakness in internal controls, despite a stated focus on a promising industry.

Positives

• The company has a stated strategic objective to advance cellular and regenerative medicine, focusing on stem cell-based applications and exosome-related innovations.
• Management believes internally reported testing indicates materially higher exosome concentration levels compared to conventional MSC cultures, though not independently validated.
• The company's research and development team has received multiple honors, including Taiwan National Innovation Awards.
• The company has a deferred payment agreement for $2,411,000 of accounts payable owed to a related party, deferring collection efforts for 24 months from May 18, 2026.
• New management has been appointed, potentially bringing a fresh strategic direction.

Negatives

• The company has generated no revenue in fiscal years 2025 and 2024.
• A substantial doubt exists regarding the company's ability to continue as a going concern, with insufficient liquidity to fund operations for the next twelve months without additional financing.
• Total liabilities ($4,029,578) substantially exceed total assets ($14,378).
• The company has a significant accumulated deficit of $5,281,503.
• The company has a material weakness in internal control over financial reporting.
• The company has no committed financing arrangements.
• The company does not currently hold any issued patents or registered trademarks.
• The company has no full-time employees other than its sole executive officer and director.
• The company's common stock is thinly traded on the OTC Pink marketplace, with limited liquidity and potential for significant price volatility.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern due to lack of revenue, minimal cash, and significant liabilities.
• The company has not commenced commercial operations, clinical trials, or obtained regulatory approvals.
• Future success is dependent on securing sufficient capital, recruiting qualified personnel, obtaining regulatory approvals, protecting intellectual property, establishing manufacturing capabilities, and entering into strategic partnerships.
• If the company pursues regenerative medicine or biologic-based products, it will be subject to extensive and evolving regulatory requirements from agencies like the FDA.
• The company does not currently hold any issued patents and relies on trade secrets, which are difficult to protect.
• Significant obligations to related parties exist, and the continuation of their financial support is not assured.
• The company's governance structure, with a single director, increases the risk of conflicts of interest.
• Former officers are involved in civil and criminal proceedings in Taiwan, which could indirectly affect the company through reputational harm or disruption of business relationships.
• A material weakness in internal control over financial reporting exists due to insufficient segregation of duties and lack of personnel with appropriate expertise.
• The company will require substantial additional capital, and future equity issuances may be highly dilutive.
• Net operating loss carryforwards may be limited under Section 382 of the Internal Revenue Code.
• The company may not meet the financial and governance requirements necessary to uplist to OTCQB or a national securities exchange.
• The company's common stock may be subject to penny stock regulations, reducing liquidity and investor interest.
• The company does not maintain a formal cybersecurity risk management framework and relies on third-party providers, exposing it to potential breaches.

Future Outlook

The company anticipates needing substantial additional capital to fund operations, research, and regulatory initiatives over the next twelve months. Management is exploring various financing options, including equity and debt securities, and strategic partnerships. Without sufficient financing, the company may need to delay or scale back its business plan. The company's ability to continue operations is dependent on raising funds and generating future revenue.

Management Comments

• Management believes that internally reported testing has indicated materially higher exosome concentration levels compared with certain conventional MSC cultures.
• Management anticipates that X.msc-based projects will progress to limited hospital implementation within approximately five years.
• Management concluded that substantial doubt exists regarding our ability to continue as a going concern within twelve months from the issuance of our financial statements.
• Management assessed the effectiveness of our internal control over financial reporting and concluded that it was not effective as of January 31, 2025, due to a material weakness.

Industry Context

StockSavvy.ai notes that VitaSpring Biomedical operates in the rapidly growing regenerative medicine and functional wellness industry, which is characterized by significant innovation and evolving regulatory landscapes. The company's focus on stem cells and exosomes aligns with key industry trends such as the growth of cell-based therapies and the shift towards personalized medicine. However, the highly fragmented and competitive nature of this industry, coupled with the company's early-stage development status and lack of resources, presents significant challenges.

Comparison to Industry Standards

• The global regenerative medicine market was estimated at approximately $48 billion in 2025 and projected to grow to $58 billion in 2026, indicating a strong growth trend that VitaSpring aims to capitalize on.
• The company aims to establish advanced medical research and cell production centers meeting Good Tissue Practice (GTP) standards, which is an industry standard for quality and safety in cell therapy manufacturing.
• VitaSpring's R&D team has received multiple honors, including Taiwan National Innovation Awards, suggesting a level of recognition within its scientific community.
• The company's strategy to develop proprietary processes for cell isolation, expansion, and exosome production aims to align with Good Manufacturing Practice (GMP) principles, a critical industry standard for pharmaceutical and biological product manufacturing.

Management Changes

Corporate Governance

Legal Proceedings

• The company is not currently involved in any legal proceedings.
• Certain former officers are involved in civil and criminal proceedings in Taiwan relating to alleged unauthorized use of proprietary know-how and intellectual property. The company is not a named party to these proceedings.

Related Party Transactions

• As of January 31, 2025, the company owed $2,411,000 to a related-party vendor owned by a former officer.
• As of January 31, 2025, the company had $810,105 in advances from related parties, including advances from a former CEO and Chairman.
• On May 18, 2026, the company entered into a deferred payment agreement with a related party to defer collection efforts for $2,411,000 of accounts payable for 24 months.
• The company has not adopted a formal related-party transaction policy.

Stakeholder Impact

• Shareholders: Potential for significant dilution from future capital raises, difficulty in trading shares due to low liquidity, and risk of losing entire investment due to the speculative nature of the stock and going concern issues.
• Creditors: Substantial portion of liabilities consists of unsecured obligations to related parties and vendors, which may be payable on demand, potentially leading to default or insolvency proceedings.
• Employees: Currently, the company has no full-time employees other than its sole executive officer, indicating minimal immediate impact on a broader employee base.
• Suppliers: Potential for delayed payments given the company's liquidity challenges and reliance on related-party financing.

Next Steps

• Regain full compliance with periodic reporting obligations under the Securities Exchange Act of 1934.
• Secure substantial additional capital to fund operations, research, and regulatory initiatives.
• Develop, commercialize, and market functional-medicine and nutraceutical formulations.
• Establish advanced medical research and cell production centers meeting Good Tissue Practice (GTP) standards.
• Develop high-quality stem cell preparations for regenerative therapies and potential future drug development.
• Progress X.msc-based projects to limited hospital implementation within approximately five years.
• Pursue development of a stem cell bank designed to operate in compliance with applicable FDA regulations.
• Implement a formal cybersecurity risk assessment and governance policy by Q3 2026.
• Adopt a Code of Business Conduct in Q2 2026.
• Evaluate the formation of appropriate Board committees as operations grow.

Key Dates

Keywords

VitaSpring Biomedical, 10-K, Annual Report, Biomedical, Regenerative Medicine, Stem Cells, Exosomes, Nutraceuticals, Development Stage, Going Concern, Financial Statements, SEC Filing, Nevada